Eyes On the Prize: From Sicilian Roots to FDA Approval
Historically, SIFI has been a modest local player focused on ophthalmic products, but in recent years the company has set some ambitious goals for itself—becoming a leading force in European…
Address: Viale Shakespeare, 47 – 00144 Rome,Italy
Tel: +39.06.592.64.43
Sigma-tau is a leading Italian pharmaceutical group, established in 1957 that counts today 2432 employees worldwide amongst whom about 400 researchers. It reached a turnover of 605 million euros in 2008.
The headquarters of the group are in Pomezia, and Sermoneta – in the province of Latina- has active installations Biosint for the production of pharmaceutical raw materials, of L-carnitine and its derivatives.
In 2001 was established BiofuturaPharma, based in Milan, that aims to develop pharmaceuticals for the treatment of diseases of the central nervous system and respiratory system. Recently the business has extended to the development and commercialization of products derived from the biological system of carnitine.
Sigma-Tau works through the National Organization for Rare Disorders (NORD) to provide patient assistance programs to help ensure that patients who are underinsured or otherwise financially limited receive their products at little or no cost.
Always investing in research, 16% of turnover in 2008, Sigma-tau aims to continue its development by:
* Increasing commitment to research in biopharma
* Continuous technological upgrading of production systems
* High-quality products
Historically, SIFI has been a modest local player focused on ophthalmic products, but in recent years the company has set some ambitious goals for itself—becoming a leading force in European…
Seasoned executive Pierluigi Antonelli went from a career in big pharma to Angelini Pharma, a midsized Italian company that has been undergoing major transformation. He shares the motivation behind the…
Collectively representing almost 400 companies operating in Italy, Farmindustria, Egualia (formerly Assogenerici) and Assobiotec respectively promote the interests of innovative pharmaceutical companies—both foreign and Italian-owned— the generics, biosimilars and value-added…
As the European Union’s largest beneficiary of the Next Generation EU (NGEU) package, aimed at boosting the EU’s economy following the COVID-19 pandemic, Italy will receive some EUR 235 billion…
While Italy’s biotech landscape is generally held to be somewhat immature in comparison to more established markets such as Germany, France or the UK, that does not imply a deficit…
Dr Nicola Normanno, the Director of the Translational Research Department of one of Italy’s national cancer institutes, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, and president of the Italian Cancer…
Tiziana Mele, managing director of Lundbeck Italia, explains the impact of COVID on mental health care from the perspective of a company dedicated to brain health, outlines the Italian operation…
Guerbet’s Alessandro Bocci – General Manager Italy & Iberia – describes the nearly 100-year-old company’s firm position in the field of contrast media for radiology and its plans for developing…
Medtronic’s Michele Perrino, Regional VP North Western Europe & Italy, Cardiovascular Commercial Partnership WE, outlines the company’s change in positioning from medtech to healthcare technology and the central role of…
Giuseppe Maduri, Chairman, Managing Director, General Manager Italy, Greece, Cyprus, Malta at Astellas Pharma explains the Japanese company’s focus on unmet needs and how Italy, one of its top European…
Chairman & Managing Director of B. Braun Milano, Klaus D. Pannes, shares the importance of the German medtech’s Italian affiliate, one of its top ten by third-party sales, which is…
Paivi Kerkola, Country Manager, Managing Director and President of Pfizer Italy, speaks about the peculiarities of the Italian market from a northern European perspective, her priorities, and the impact of…
See our Cookie Privacy Policy Here
